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Abstract 
Background: In Pompe disease, an inherited metabolic muscle disorder, severe diaphragmatic weakness often 
occurs. Enzyme replacement treatment is relatively ineffective for respiratory function, possibly because of irreversible 
damage to the diaphragm early in the disease course. Mildly impaired diaphragmatic function may not be recognized 
by spirometry, which is commonly used to study respiratory function. In this cross-sectional study, we aimed to iden-
tify early signs of diaphragmatic weakness in Pompe patients using chest MRI.
Methods: Pompe patients covering the spectrum of disease severity, and sex and age matched healthy controls 
were prospectively included and studied using spirometry-controlled sagittal MR images of both mid-hemidia-
phragms during forced inspiration. The motions of the diaphragm and thoracic wall were evaluated by measuring 
thoracic cranial-caudal and anterior–posterior distance ratios between inspiration and expiration. The diaphragm 
shape was evaluated by measuring the height of the diaphragm curvature. We used multiple linear regression analy-
sis to compare different groups.
Results: We included 22 Pompe patients with decreased spirometry results (forced vital capacity in supine position 
< 80% predicted); 13 Pompe patients with normal spirometry results (forced vital capacity in supine position ≥ 80% 
predicted) and 18 healthy controls. The mean cranial-caudal ratio was only 1.32 in patients with decreased spirometry 
results, 1.60 in patients with normal spirometry results and 1.72 in healthy controls (p < 0.001). Anterior–posterior ratios 
showed no significant differences. The mean height ratios of the diaphragm curvature were 1.41 in patients with 
decreased spirometry results, 1.08 in patients with normal spirometry results and 0.82 in healthy controls (p = 0.001), 
indicating an increased curvature of the diaphragm during inspiration in Pompe patients.
Conclusions: Even in early-stage Pompe disease, when spirometry results are still within normal range, the motion 
of the diaphragm is already reduced and the shape is more curved during inspiration. MRI can be used to detect early 
signs of diaphragmatic weakness in patients with Pompe disease, which might help to select patients for early inter-
vention to prevent possible irreversible damage to the diaphragm.
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Background
Respiratory insufficiency due to muscle weakness is often 
observed in patients with muscle disease, and is a typi-
cal characteristic of patients with advanced Pompe dis-
ease, an autosomal recessive metabolic myopathy caused 
by a deficiency of acid alpha-glucosidase [1–3]. Respira-
tory dysfunction in Pompe patients is caused mainly by 
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weakness of the diaphragm, and is demonstrated by a 
decreased forced vital capacity (FVC) particularly in 
supine position [4, 5]. In adults with non-classic Pompe 
disease, treatment with enzyme replacement therapy 
(ERT) resulted in an improved walking distance and 
muscle strength and stabilizing of respiratory function 
[6–10]. However, the effect of ERT is much smaller on 
respiratory function than on skeletal muscle function [7, 
9, 10]. The international guideline for starting ERT, indi-
cates that ERT should start when patients have skeletal 
muscle weakness and/or respiratory muscle weakness 
defined as an forced vital capacity (FVC) of below 80% 
predicted [11]. However, it is possible that damage to the 
diaphragm had already become irreversible before ERT 
was started. Early recognition of diaphragmatic weakness 
is important to allow a timely start of treatment, which 
is even more important as new therapies are currently 
tested or are in a preclinical phase.
Routine pulmonary function tests, such as vital capac-
ity, FVC and mean inspiratory and expiratory pressures 
(MIP and MEP) do not differentiate between the function 
of the diaphragm and the intercostal muscles [5, 12, 13]. 
Improved insight into the contribution of the different 
respiratory muscles to inspiration can be provided using 
spirometry-controlled MRI, evaluating the entire dia-
phragm and thoracic wall during respiratory movements 
[14].
Using MRI, the predominantly involvement of the dia-
phragm in Pompe was shown in patients with advanced 
muscular involvement [15–18]. However, these studies 
do not reveal when diaphragmatic weakness starts, and 
whether an impaired diaphragm function is initially com-
pensated by other respiratory muscles, resulting in nor-
mal pulmonary function tests results.
The aim of this study was to identify early signs of 
diaphragmatic weakness. We therefore used advanced 
image-analysis techniques to evaluate the motion and 
shape of the diaphragm in detail. We included a large 
group of children and adults with Pompe disease cover-
ing the spectrum of disease severity, ranging from those 
with normal spirometry results to those who need noc-
turnal ventilation due to respiratory dysfunction.
Methods
Study design and participants
In this cross-sectional study, we conducted spirometer-
controlled MRI scans in Pompe patients (age ≥ 8  years) 
and healthy controls who had been matched for sex and 
age. Pompe patients who visited the Center for Lysoso-
mal and Metabolic Diseases at Erasmus MC University 
Medical Center, the reference center for Pompe disease 
in the Netherlands, were consecutively invited to partici-
pate between January 2016 and February 2018. Inclusion 
criteria were a confirmed diagnosis of non-classic Pompe 
disease (based on two disease causing variants in the acid 
alpha-glucosidase gene and/or decreased enzyme activity 
in fibroblasts) and the ability to lie in a supine position 
for at least 30 min without mechanical ventilation. Exclu-
sion criteria were comorbidities or devices that did not 
permit MRI investigations, and claustrophobia. The pro-
tocol was approved by the Medical Ethical Committee at 
our hospital (MEC-2007-103, amendment 7). All partici-
pants provided written informed consent.
Pulmonary function tests
Before MRI, pulmonary function tests were performed 
according to ATS/ERS standards [19]. FVC was meas-
ured with the patient in upright seated and supine posi-
tions. MIP and MEP were measured with the patient in 
the upright position. All respiration maneuvers were 
repeated three times and the best effort was used in fur-
ther analysis. Results were expressed as a percentage of 
predicted normal values [20, 21].
MRI analysis
All patients were examined on a 3 T GE Signa 750 MRI 
(General Electric Healthcare, Milwaukee, Winconsin, 
USA), using the whole-body coil for radio-frequency 
excitation and a 32-channel torso coil for signal recep-
tion. We developed a new MRI scanning protocol includ-
ing end-expiration and end-inspiration breath-hold 
acquisitions, followed by dynamic acquisitions dur-
ing forced expiration, forced inspiration, and the sniff 
maneuver (Table 1). To ensure that all breathing maneu-
vers were executed correctly and with maximum effort, 
all breathing maneuvers were performed before and dur-
ing MRI using a MR compatible spirometer, with instruc-
tions given through headphone. The overall acquisition 
time per patient was 20–25 min.
In this study, we used dynamic sagittal bi-dimensional 
(2D) images, starting at breath holding at end-expiration, 
followed by a forced inspiration maneuver, and ending 
at breath holding at end-inspiration. The sagittal levels 
were manually selected at the right and left mid-hemidia-
phragm using the three-dimensional (3D) breath holding 
acquisition at end-inspiration.
Image segmentation
We selected the images during the inspiration maneu-
ver, comprising ± 15 of 60 images. Manual image seg-
mentation was performed by two observers (LH and AP) 
using ITK-SNAP (Version 3.6.0 Apr 1, 2017, Copyright 
© 1998–2017, www.itksn ap.org) [22]. This free, open-
source software application enables to manually indicate 
the area of the lung on the selected images. Anterior and 
posterior points of the insertion of the diaphragm were 
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chosen as reference points for basal lung contours. For 
the left lung, the heart was included in the segmented 
lung area to optimally delineate the contours of the dia-
phragm (Fig. 1a, b).
Automatic measurements
The segmentations were analyzed with a custom-built 
Python script (Python 3.6.3, https ://www.pytho n.org/, 
©2001–2019. Python Software Foundation; SciPy 1.1.0, 
https ://www.scipy .org/, ©2003–2019 SciPy develop-
ers) (Fig. 1c). The algorithm first determines the general 
orientation of the lung, to correct for minor differences 
in position between patients, by fitting an ellipse to the 
points on the lung outline. The lung apex is then defined 
as the highest point on the lung outline, measured in the 
direction of the major axis of the ellipse. The algorithm 
then detects the anterior and posterior costophrenic 
angles of the diaphragm, defined as the points with the 
largest distance to the centroid (center of gravity) in the 
lower part of the lungs. The diaphragm apex was defined 
as the point on the diaphragm contour that is furthest 
away from the linear line between both costophrenic 
angles of the diaphragm. Because for some patients this 
maximum-distance point was quite variable between 
consecutive frames, we used a derived diaphragm apex: 
therefore, the relative position of the diaphragm apex 
along the diaphragm contour was computed in each 
frame as a percentage of the diaphragm length; then, 
the median position of all frames was computed and this 
median relative distance was used for each frame to com-
pute the derived diaphragm apex. All reference points 
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TRICKS 3D SPGR DISCO
Orientation
Sagittal Sagittal





(ms) 1.2 1.0 2.3 1.0 1.0 1.0
Echo time (ms) 0.5 0.3 0.8 0.3 0.4 0.3
Field of view (cm) 36 48 36 48 48 48
Percent phase 
field of view 
sampling
50% 75% 50% 50% 50%
Matrix
Flip angle 2° 1° 7° 1° 1° 1°
Voxel-resolution 
(mm) isotropic isotropic isotropic isotropic
Temporal 
resolution (ms) 250 200 785 260 250
Scan time (s) 6-10 10 11 12 2-14 10
Number of slices Depending on 
the size of 
patient
42 1 right and 1 left 
Depending on 
the size of 
patient
42 42
120 × 120 48 × 48 100 × 100 48 × 48 48 × 48 48 × 48
3 × 3 × 3 isotropic 10 × 10 × 10 3.6 × 3.6 × 10 10 × 10 × 10 10 × 10 × 10 10 × 10 × 10
MRI protocol and parameters on 3 T GE Signa 750 MRI (General Electric Healthcare, Milwaukee, USA) with a 32-channel torso coil. The acquisition for this part of the 
study is marked with thick borders and included 2D dynamic inspiratory SPGR multiphase sagittal acquisition at the level of the right and left mid-hemi-diaphragm. 
All dynamic inspiration acquisitions started with breath holding at end-expiration and ended with breath holding at end-inspiration. Dynamic forced expiration 
started with breath holding at end-inspiration and ended with breath holding at end-expiration
2D = bi-dimensional, 3D = three-dimensional, Disco = DIfferential Sub-sampling with Cartesian Ordering, SPGR = spoiled gradient echo, Tricks = time-resolved 
imaging of contrast kinetics, FSGPR = fast spoiled gradient echo
a After respective 3D SPGR inspiratory and expiratory localizer sequences
b Sequence will be repeated after 2D FSPGR sequence
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were visual inspected by LH and GT to confirm that the 
points were correctly indicated.
MRI outcome measures
Four thorax-related outcomes and four diaphragm-
related outcomes were measured at end-expiration and 
end-inspiration (Fig.  1d, e). To correct for anatomical 
variations between individual patients, we calculated 
ratios by dividing end-inspiration outcomes by end-expi-
ration outcomes.
Thorax‑related outcomes
The cranial-caudal (CC) distance was measured as the 
distance between the lung apex and diaphragm apex to 
evaluate diaphragmatic motion. The anterior–posterior 
(AP) distance is the longest distance from the front to the 
back of the lung to evaluate motion of the thoracic wall. 
To calculate the diaphragm motion relative to the motion 
of the thoracic wall, the CC-AP ratio was calculated by 
dividing the CC ratio by the AP ratio. The lung area is the 
area of the segmentation to evaluate the result of all res-
piratory muscles together. For the left hemi-diaphragm, 
lung area included the area of the heart to reduce the 
effect of heart size.
Diaphragm‑related outcomes
To evaluate the shape of the diaphragm, the area below 
the diaphragm curvature (DA) and the height of the dia-
phragm curvature (DH) were measured to calculate the 
DA ratio and DH ratio between inspiration and expira-
tion. The DA is the area between the diaphragm contour 
and the linear line connecting both diaphragm corners. 
The DH is the perpendicular distance between the dia-
phragm apex and the linear line. In addition, the absolute 
displacements of the anterior and posterior costophrenic 
angles of the diaphragm were measured in consecutive 
images from end-expiration to end-inspiration.
Validation of measurements
To validate automatic measurements, manual measure-
ments of thorax related outcomes were performed by two 
independent observers (LH and AP). CC distance and 
AP distance were measured using ITK-SNAP and lung 
area was measured with Aw Server (2.0 General Electric 
Healthcare © 2009–2012). All automatically measured 
thorax-related outcomes were compared to manually 
measured outcomes. Second, both observers performed 
all measurements twice in 5 patients (9%) to calculate 
intra-observer variability and in 10 similar patients (19%) 
to calculate inter-observer variability. These measure-
ments included new segmentations on end-expiration 
and end-inspiration images. We used intra-class correla-
tion coefficients (ICC) based on absolute-agreement and 
two-way mixed-effects model [23]. Bland–Altman plots 
were inspected to assess possible systematic errors.
Statistical analysis
To investigate early signs of diaphragmatic weakness, 
we subdivided the Pompe patients into two subgroups: 
patients with normal spirometry results (FVC supine 
≥ 80% than predicted and z-score ≥ −1.64) and patients 
with decreased spirometry results (FVC supine < 80% 
and z-score < −1.64).
To analyze differences in patient characteristics and 
pulmonary function outcomes between the two sub-
groups of Pompe patients and the healthy controls, we 
used the chi-square test for categorical variables and the 
Kruskal Wallis test for continuous variables. The Mann–
Whitney test was used to test for differences in disease 
duration and duration of ERT between the two subgroups 
of Pompe patients. Overall differences in MRI outcomes 
and differences between healthy controls and the two 
subgroups of Pompe patients were analyzed using mul-
tiple linear regression analysis, with adjustment for sig-
nificant differences in patient characteristics between the 
three subgroups. Residual plots were inspected to check 
the linearity assumption. The Spearman correlation coef-
ficient was used to calculate the strength of association 
between the pulmonary function test outcomes and the 
MRI outcomes.
All analyses were performed on the left and right sides 
of the thorax. Because segmentation of the left hemidia-
phragm is more cumbersome due to the heart, we report 
only the results of the right hemidiaphragm.
Statistical analysis was performed with SPSS for Win-
dows (version 25, SPSS Inc, Chicago, IL). The significance 
level was set at p ≤ 0.05. Unless indicated otherwise, we 
report overall differences between the three subgroups. 
Differences between subgroups were corrected for mul-
tiple testing using Bonferroni’s method, resulting in a 
significance level of p ≤ 0.017. Due to the explorative 
Fig. 1 MRI measurements and outcomes. a, b Examples of manual image segmentation in the right and left lung at expiration and inspiration in 
an healthy control. c Steps of the automatic algorithm to define reference points to calculate the different outcome measures. d and e Thorax- and 
diaphragm-related outcomes. The grey lines depict the outlines of the lung in consecutive images from end expiration to end-inspiration. The 
red point indicates the anterior corner of the diaphragm and the blue point the posterior corner of the diaphragm. The green points indicate 
displacement of the lung apex and diaphragm apex. Purple arrows and purple areas indicate the outcome measurements
(See figure on next page.)
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character of the study, we did not adjust for multiple test-
ing when reporting the different MRI outcomes.
Results
Participants characteristics and pulmonary function tests
We included 35 patients with Pompe disease (age 
15–70  years) and 18 sex and age-matched healthy con-
trols (Table  2). Thirteen patients had spirometry results 
in the normal range (FVC supine ≥ 80%); none of these 
patients had significant dyspnea or signs of nocturnal 
hypoventilation. Twenty-two patients had decreased 
spirometry results (FVC supine < 80%), one of whom 
used nocturnal non-invasive ventilation due to hyper-
capnia. Patients with normal spirometry results were 
younger, had a shorter disease duration since symptom 
onset, and fewer of them had been treated with ERT 
than patients with decreased spirometry results. Healthy 
controls had better FVC, MIP and MEP outcomes than 
Pompe patients. None of the patients had a significant 
kyphoscoliosis needing surgery or referral to an orthope-
dic surgeon.
Thorax‑related outcomes
The mean CC ratios were as follows: 1.72 in healthy 
controls, 1.60 in Pompe patients with normal spirom-
etry results, and 1.32 in Pompe patients with decreased 
spirometry results (p < 0.001). The mean AP ratio did 
not differ significantly between the three subgroups. The 
mean lung area ratios were 2.54 in healthy controls, 2.57 
in Pompe patients with normal spirometry results, and 
1.95 in Pompe patients with decreased spirometry results 
(p = 0.001). The mean CC-AP ratios were 1.38 in healthy 
controls, 1.22 in Pompe patients with normal spirom-
etry results, and 1.04 in Pompe patients with decreased 
spirometry results (p < 0.001). While patients with normal 
spirometry results had lower CC ratios and CC-AP ratios 
than healthy controls (p = 0.002 and p = 0.005), their lung 
area ratios were not significantly different (Fig. 2).
The agreement between automatic and manual meas-
urements was excellent (ICC range 0.93–0.99), and the 
intra- and inter-observer agreement between man-
ual measurements was good to excellent (ICC range 
0.80–0.99).
Diaphragm‑related outcomes
During inspiration, DA and DH in healthy controls 
decreased, indicating a decreased curvature of the dia-
phragm. In Pompe patients, however, the curvature 
of the diaphragm remained equal or increased during 
inspiration. In healthy controls mean DA ratio was 0.91 
and mean DH ratio 0.82, in Pompe patients with normal 
spirometry results mean DA ratio was 1.34 and mean 
DH ratio was 1.08, and in those with decreased spirom-
etry results was mean DA ratio was 1.79 (p < 0.01) and the 
mean DH ratio was 1.41 (p < 0.01). In healthy controls, 
the absolute displacement of the posterior costophrenic 
Table 2 Participant characteristics
Characteristics and outcomes of pulmonary function tests of Pompe patients and healthy controls. Continues values are presented as mean ± standard deviation and 
were tested using the Mann Whitney or Kruskal Wallis tests. Categorical values are presented as number with percentage and were tested with the chi square test. 
P-values indicate overall differences between groups
BMI = body mass index, ERT = enzyme replacement therapy, FVC = forced vital capacity, Δ FVC = FVC upright – FVC supine, MIP = maximum inspiratory pressure, 
MEP = maximum expiratory pressure
Pompe patients with decreased 
spirometry results
(FVC supine
 < 80%) (n = 22)
Pompe patients with normal 
spirometry results
(FVC supine




Sex, number of males (%) 11 (50%) 7 (54%) 8 (44%) 0.869
Age, years 45 ± 16 31 ± 14 43 ± 14 0.030
Height, cm 178 ± 11 174 ± 9 178 ± 12 0.761
Weight, kg 76 ± 16 70 ± 13 79 ± 14 0.291
BMI, kg/m2 24 ± 4 23 ± 4 25 ± 3 0.262
Disease duration, years 16 ± 8 9 ± 9 – 0.018
Patients on ERT, n (%) 18 (82%) 6 (46%) – 0.028
Duration of ERT, years 6 ± 5 6 ± 4 – 0.811
Non-invasive ventilation, n (%) 1 (3%) 0 (0%) – 0.435
FVC upright, % of predicted 81 ± 11 97 ± 9 106 ± 8  < 0.001
FVC supine, % of predicted 60 ± 12 94 ± 9 102 ± 8  < 0.001
Δ FVC, % of predicted 21 ± 10 4 ± 4 4 ± 4  < 0.001
MIP, % of predicted 72 ± 23 88 ± 28 106 ± 25 0.001
MEP, % of predicted 80 ± 28 81 ± 28 112 ± 28 0.002
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angle of the diaphragm was larger than the displace-
ment of the anterior costophrenic angle. Mean absolute 
displacement of the posterior costophrenic angle was 
70.7 mm in healthy controls, 70.6 mm in Pompe patients 
with normal spirometry results, and 35.6 mm in Pompe 
patients with decreased spirometry results (p < 0.001). 
Mean absolute displacement of the anterior costophrenic 
angle did not differ between healthy controls and the 
two groups of Pompe patients. In patients with normal 
spirometry results, the DA and DH ratios were higher 
than in healthy controls (p = 0.088 and p = 0.034, which 
was not significant after Bonferroni’s correction) (Fig. 3).
Fig. 2 Thorax-related outcomes on the right side. The scatter plots present the thorax-related outcomes on the right side of the thorax in the 
two subgroups of Pompe patients and in healthy controls. Error bars show means with standard deviations. FVC = forced vital capacity in supine 
position. HC = healthy controls, PD = patients with Pompe disease. P-values < 0.017 are indicated with * as statistically significant, according to 
Bonferroni’s method for correcting for multiple testing. o means not statistically significant
Fig. 3 Diaphragm-related outcomes on the right side. The scatter plots present the diaphragm-related outcomes on the right side of the thorax in 
the two subgroups of Pompe patients and in healthy controls. Error bars show means with standard deviations. FVC = forced vital capacity in supine 
position. HC = healthy controls, PD = patients with Pompe disease. P-values < 0.017 are indicated with * as statistically significant, according to 
Bonferroni’s method for correcting for multiple testing. o means not statistically significant
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Levels of diaphragmatic weakness
Using MRI to assess diaphragmatic weakness, different 
levels of severity could be indicted (Fig.  4). In patients 
with severe diaphragmatic weakness, the diaphragm 
shows hardly any motion and the CC ratio is ~ 1. Those 
with moderate diaphragmatic weakness still have dia-
phragmatic motion (CC ratio > 1), although it is lower 
than that in healthy controls. In patients with mild dia-
phragmatic weakness, the CC ratio is normal, but DA 
ratio and DH ratio are increased, indicating an increased 
curvature of the diaphragm compared to in healthy con-
trols and patients without diaphragmatic weakness. 
Importantly, in patients with mild or moderate diaphrag-
matic weakness, AP ratio is still normal or increased, 
indicating an increased motion of the thoracic wall. The 
large contribution to inspiration of the thoracic wall rela-
tive to that of the diaphragm is also reflected by a lower 
CC-AP ratio.
Correlation between pulmonary function tests 
and MRI‑outcomes
CC ratio, CC-AP ratio and absolute displacement of the 
posterior corner of the diaphragm, outcomes evaluat-
ing the motion of the diaphragm, showed the best cor-
relations with FVC supine (> 0.64) and Δ FVC (<−0.59) 
(Table  3). The correlations of these MRI outcomes with 
FVC upright and MIP, which lay between 0.32 and 0.52, 
showed that upright pulmonary function tests provided 
less information on the motion of the diaphragm than 
supine pulmonary function tests. The MRI outcomes that 
measure the curvature of the diaphragm during inspira-
tion—the DA and DH ratios—showed moderate correla-
tions with FVC supine (<−0.58) and Δ FVC (>0.48). The 
low correlations of MEP with all MRI outcomes (<0.3) 
indicate that this test does not have the sensitivity neces-
sary for measuring diaphragmatic motion or shape.
Discussion
In this cross-sectional study we used 2D sagittal dynamic 
MRI to evaluate the motion and shape of the diaphragm 
in children and adults with non-classic Pompe disease 
who had normal or decreased spirometry results. We 
found that motion of the diaphragm is decreased in 
patients with Pompe disease, and that the curvature of 
the diaphragm in these patients is increased during inspi-
ration. Interestingly, these MRI signs were observed even 
in Pompe patients whose spirometry results were still 
within the normal range. This means that MRI enables 
to detect early signs of diaphragmatic weakness. These 
results are important for Pompe patients, but poten-
tially also for patients with other neuromuscular disease 
having respiratory dysfunction, because early recogni-
tion of impaired diaphragmatic function enables to start 
early interventions to prevent irreversible damage to the 
diaphragm.
Our observations show a clear dissociation between 
the loss of function of the diaphragm and the intercos-
tal musculature. Diaphragmatic weakness is common 
in adults with Pompe disease, and earlier 2D and 3D 
MRI pilot studies in small groups of Pompe patients 
with decreased spirometry results also found decreased 
motion of the diaphragm [15–18]. Interestingly, this is 
different compared to studies in patients with Duchenne 
muscular dystrophy, in whom the motion of the chest 
wall as well as the diaphragm are reduced [24]. As we 
wished to investigate whether early signs of diaphrag-
matic weakness could also be observed in Pompe patients 
with normal spirometry results, we conducted the cur-
rent MRI study. A remarkable finding was that while 
motion of the thoracic wall still lay in the normal range, 
motion of the diaphragm was already less than in healthy 
controls. Early involvement of the diaphragm might be an 
explanation for the presentation with respiratory symp-
toms without limb girdle muscle weakness in in a subset 
of patients with Pompe disease [25, 26].
A second finding was that Pompe patients had an 
increased curvature of the diaphragm during inspira-
tion compared to healthy controls. We hypothesize that 
the aberrant shape of the diaphragm during inspiration is 
caused by diaphragmatic weakness. In healthy controls, 
during inspiration, intrathoracic pressure is reduced and 
abdominal pressure is increased by the downward move-
ment of the diaphragm and the outward movement of the 
chest wall [27, 28]. In patients with severe diaphragmatic 
weakness, however, the lower intrathoracic pressure and 
impaired tonus of the diaphragm result in an upward 
paradoxical displacement of the diaphragm [28]. As many 
Pompe patients also have abdominal muscle weakness, 
(See figure on next page.)
Fig. 4 Levels of diaphragmatic weakness. Examples of a healthy control and of four Pompe patients with different levels of diaphragmatic 
weakness. The left-hand images show the sagittal MRI at end-expiration and end-inspiration. The grey outlines show the contours of the lungs from 
expiration to inspiration (bold lines). The blue point is the posterior corner of the diaphragm and the red point the anterior corner. The green points 
show the lung apex and diaphragm apex. The individual results of pulmonary function tests (% of predicted outcome) and MRI outcome ratios are 
also reported, with red numbers indicating abnormal outcomes compared to healthy controls. FVC = forced vital capacity, Δ FVC = FVC upright – 
FVC supine, MIP = maximum inspiration pressure, MEP = maximum expiration pressure, CC ratio = cranial-caudal ratio, AP ratio = anterior posterior 
ratio, CC-AP ratio = CC ratio / AP ratio, DH ratio = diaphragm height ratio, DA ratio = diaphragm area ratio
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abdominal pressure will not increase sufficiently during 
inspiration. Consequently, there is little or no paradoxi-
cal movement of the diaphragm, but only a paradoxical 
increased curvature of the diaphragm during inspiration.
An important question is why the preferential weak-
ness of the diaphragm compared to the intercostal mus-
cles occurs. In healthy adults, the diaphragm comprises 
an equal distribution of slow-twitch type-1 fibers and 
fast-twitch type-2 fibers, while the intercostal muscles 
contain a higher proportion of fast-twitch type-2 fibers 
[27, 29, 30]. In Pompe patients, it is known that damage 
to skeletal muscle includes both muscle fiber types, but 
there have been no studies on the involvement of specific 
respiratory-muscle fiber types [31]. Early damage of the 
diaphragm however could also be facilitated by the fact 
that this muscle and tendon plate is relatively thin [32].
As our study showed that FVC supine and the differ-
ence between FVC upright and FVC supine (Δ FVC) 
had the highest correlations with the motion of the 
diaphragm as measured with MRI, these pulmonary 
function tests are important parameters to diagnose dia-
phragmatic weakness. While weakness of the diaphragm 
is usually clear in patients with FVC supine < 80%, our 
dynamic MRI protocol can be used to demonstrate a 
different shape or reduced motion of the diaphragm in 
patients with an FVC ≥ 80%, which is considered to be in 
the normal range [11].
Ultrasound is another technique to investigate the 
diaphragm. In Pompe patients, it showed a reduced 
diaphragmatic thickness and motion and a good cor-
relation with FVC in seated and supine position [33]. 
While ultrasound logistically might be more easy to 
perform, a comparison between diaphragmatic motion 
and motion of intercostal muscles and a more detailed 
evaluation of the curvature of the diaphragm is not 
possible. Therefore, detection of slight diaphragmatic 
weakness in an early stage of Pompe disease using 
ultrasound will likely be difficult.
By using our new 2D sagittal dynamic MRI protocol, 
we were able to identify reliable automatically meas-
ured outcome measures to characterize the motion and 
shape of the diaphragm. Our automatic measurements 
are operator independent and showed excellent corre-
lation with manual measurements.
Our study however has some limitations. Spirom-
etry-controlled MRI is logistically more difficult and 
expensive than regular pulmonary function tests. Sec-
ond, segmentations were performed manually and were 
time consuming. Further development of automatic 
measurements, including automatic segmentations 
would be useful. Additional investigation is required to 
determine whether this chest MRI technique may also 
be useful to detect a potential neuromuscular cause in 
patients who present with dyspnea and/or respiratory 
failure of unknown origin. To generate reference values 
for our MRI outcomes, the population of healthy con-
trols should be further increased.
Conclusions
We have demonstrated that MRI is a sensitive tool 
for detecting early stages of diaphragmatic weakness 
in patients with Pompe disease, even when spirom-
etry results are within the normal range. MRI provides 
insight into the process of increasing diaphragmatic 
weakness, and when FVC starts to decline, possi-
ble irreversible functional changes of the diaphragm 
may have already taken place. This may explain 
Table 3 Correlation between MRI outcomes and pulmonary function tests outcomes
Spearman correlation coefficients between thorax-related outcomes and diaphragm-related outcomes (ratios between end-inspiration and end-expiration outcomes) 
and outcomes of pulmonary function tests (% predicted). Significant correlations are indicated with *p < 0.05, **p < 0.01 or ***p < 0.001
CC-AP ratio = cranial caudal ratio / anterior posterior ratio. FVC = forced vital capacity, Δ FVC = FVC upright—FVC supine, MEP = mean expiratory pressure, MIP = mean 
inspiratory pressure
FVC upright FVC supine Δ FVC MIP MEP
Thorax-related outcomes
Cranial-caudal ratio 0.518*** 0.680*** −0.654*** 0.435** 0.187
Anterior–posterior ratio 0.035 0.097 −0.112 −0.008 0.040
Lung area ratio 0.473*** 0.636*** −0.610*** 0.398** 0.151
CC-AP ratio 0.509*** 0.643*** −0.608*** 0.403** 0.161
Diaphragm-related outcomes
Diaphragm area ratio −0.556*** −0.588*** 0.484*** −0.355** −0.293*
Diaphragm height ratio −0.538*** −0.608*** 0.552*** −0.382** −0.270
Anterior displacement 0.089 0.201 −0.234 −0.065 −0.042
Posterior displacement 0.486*** 0.650*** −0.598*** 0.322* 0.021
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why respiratory function as assessed by spirometry 
responds relatively poorly to ERT. Potentially, the MRI 
outcome measures may be helpful to optimize the start 
of treatment, and to assess diaphragmatic function and 
therapy response over time, not only in Pompe disease, 
but also in other neuromuscular diseases associated 
with respiratory dysfunction.
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